Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension

Boston University, Boston, Massachusetts, United States
Chest (Impact Factor: 7.13). 01/2006; 128(6 Suppl):618S-619S. DOI: 10.1378/chest.128.6_suppl.618S-a
Source: PubMed
Download full-text


Available from: Nicholas S Hill, Jul 05, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Phosphodiesterase-5 (PDE5) inhibitors and other agents that modulate intracellular cGMP are now emerging as promising, safe, and easy to administer therapies for pulmonary hypertension, with relatively few side effects. Recent studies have shown that PDE5 inhibitors are potent acute pulmonary vasodilators in experimental models that partially reverse established pulmonary arterial hypertension and blunt chronic pulmonary hypertension. In addition, studies on animals reveal that PDE5 inhibitors work in concert with nitric oxide and/or natriuretic peptide levels by enhancing intracellular cGMP and cGMP-mediated vasodilator effects. Further, the combination of PDE5 inhibitors and agents that increase cGMP or cAMP also yields additive beneficial effects on pulmonary hemodynamics in patients with pulmonary arterial hypertension.
    Current Opinion in Pharmacology 07/2005; 5(3):245-50. DOI:10.1016/j.coph.2004.12.008 · 4.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite reports of the efficacy of phosphodiesterase 4 (PDE4) inhibitors in some Phase III clinical trials of asthma and chronic obstructive pulmonary disease, the presence of dose-limiting side effects continue to hamper their development. Consequently, new approaches are required to improve the therapeutic ratio and the safety of these compounds. One option might lie in the synthesis of small molecules with a broader PDE specificity. The development of dual-specificity compounds that inhibit PDE4 and PDE1, PDE3, PDE5 or PDE7 could be beneficial for the treatment of chronic inflammatory lung diseases and are currently being investigated.
    Current Opinion in Pharmacology 07/2005; 5(3):238-44. DOI:10.1016/j.coph.2005.04.001 · 4.23 Impact Factor